References
- Vincent T. L., Richardson M. P., Mackworth‐Young C. G., Hawke S. H., Venables P. J. W. Sjögren's syndrome myelopathy: response to immunosuppressive treatment. Am J Med 2003; 114: 145–8
- Menage P., de Toffol B., Degenne D., Saudeau D., Bardos P., Autret A. Gougerot‐Sjogren syndrome. Central neurological involvement with recurrent development] in French. Rev Neurol 1993; 149: 554–6
- Wright R., O'Duffy J., Rodriguez M. Improvement of myelopathy in Sjögren's syndrome with chlorambucil and prednisone therapy. Neurology 1999; 52: 386–8
- Williams C. S., Butler E., Román G. C. Treatment of myelopathy in Sjögren's syndrome with a combination of prednisone and cyclophosphamide. Arch Neurol 2001; 58: 815–19
- Hermisson M., Klein R., Schmidt F., Weller M., Kuler W. Myelopathy in primary Sjögren's syndrome: diagnostic and therapeutic aspects. Acta Neurol Scand 2002; 105: 450–3
- Hawley R. J., Hendricks W. T. Treatment of Sjogren syndrome myelopathy with azathioprine and steroids. Arch Neurol 2002; 59: 875
- Vitali C., Bombardieri S., Moutsopoulos H. M., Coll J., Gerli R., Hatron P. Y., et al. Assessment of the European classification criteria for Sjögren's syndrome in a series of clinically defined cases: results of a prospective multicentre study. Ann Rheum Dis 1996; 55: 116–21
- Rogers S. J., Williams C. S., Román G. C. Myelopathy in Sjögren's syndrome. Role of nonsteroidal immunosuppressants. Drugs 2004; 64: 123–32
- Alexander E. L. Neurologic disease in Sjögren's syndrome: mononuclear inflammatory vasculopathy affecting central/peripheral nervous system and muscle. Rheum Clin Dis North Am 1993; 19: 869–908
- Alexander E. L., Ranzenbach M. R., Kumar A. J., Kozachuk W. E., Rosenbaum A. E., Patronas N., et al. Anti‐Ro (SS‐A) autoantibodies in central nervous system disease associated with Sjögren's syndrome (CNS‐SS): clinical, neuroimaging, and angiographic correlates. Neurology 1994; 44: 899–908